Somewhat Favorable News Coverage Very Unlikely to Affect Mazor Robotics (MZOR) Share Price

News headlines about Mazor Robotics (NASDAQ:MZOR) have been trending somewhat positive recently, Alpha One Sentiment Analysis reports. The research group, a division of Accern, scores the sentiment of media coverage by reviewing more than twenty million news and blog sources in real-time. Alpha One ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Mazor Robotics earned a media sentiment score of 0.01 on Alpha One’s scale. Alpha One also assigned media stories about the medical instruments supplier an impact score of 25 out of 100, indicating that recent media coverage is very unlikely to have an effect on the stock’s share price in the next few days.

Here are some of the news articles that may have effected AlphaOne’s rankings:

Insider Buying and Selling by Quarter for Mazor Robotics (NASDAQ:MZOR)

Shares of Mazor Robotics (NASDAQ MZOR) traded up 0.78% during midday trading on Friday, hitting $33.75. The stock had a trading volume of 294,629 shares. Mazor Robotics has a 1-year low of $15.79 and a 1-year high of $45.64. The firm has a 50-day moving average price of $38.48 and a 200-day moving average price of $28.05. The firm’s market cap is $805.78 million.

Mazor Robotics (NASDAQ:MZOR) last released its earnings results on Wednesday, May 10th. The medical instruments supplier reported ($0.22) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.20) by $0.02. Mazor Robotics had a negative return on equity of 30.90% and a negative net margin of 45.08%. The firm had revenue of $11.70 million for the quarter, compared to analyst estimates of $11.49 million. During the same period last year, the business earned ($0.10) earnings per share. The firm’s quarterly revenue was up 82.8% compared to the same quarter last year. On average, equities analysts anticipate that Mazor Robotics will post ($0.75) EPS for the current fiscal year.

Several equities analysts recently commented on MZOR shares. Zacks Investment Research upgraded Mazor Robotics from a “sell” rating to a “hold” rating in a research note on Saturday, April 22nd. B. Riley restated a “neutral” rating and set a $25.00 price target on shares of Mazor Robotics in a research note on Wednesday, April 19th. Needham & Company LLC restated a “hold” rating on shares of Mazor Robotics in a research note on Wednesday, May 24th. First Analysis lowered Mazor Robotics from an “overweight” rating to an “equal weight” rating and upped their price target for the stock from $28.00 to $38.00 in a research note on Thursday, May 11th. Finally, Barclays PLC lowered Mazor Robotics from an “overweight” rating to an “equal weight” rating and upped their price target for the stock from $31.00 to $32.00 in a research note on Monday, April 24th. They noted that the move was a valuation call. One investment analyst has rated the stock with a sell rating, eight have given a hold rating and one has assigned a buy rating to the company’s stock. The company has an average rating of “Hold” and a consensus target price of $33.50.

COPYRIGHT VIOLATION NOTICE: This piece of content was published by sleekmoney and is the sole property of of sleekmoney. If you are accessing this piece of content on another site, it was illegally copied and republished in violation of U.S. and international trademark & copyright laws. The original version of this piece of content can be accessed at

About Mazor Robotics

Mazor Robotics Ltd is an Israel-based medical device company that develops and markets surgical guidance systems and complementary products. It develops computerized and imaging-based systems in the field of spine surgery. Its products include: Renaissance Surgical Guidance System, which enables surgeons to advance from freehand surgical procedures to guided procedures, as well as Food and Drug Administration (FDA)-cleared and European Conformity (CE)-marked Renaissance System, used in spine surgeries, whether open or minimally invasive, for a number of clinical indications.

This story was originally published by sleekmoney ( and is the sole property of sleekmoney. If you are reading this article on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. You can view the original version of this story at

Receive News & Ratings for Mazor Robotics Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mazor Robotics Ltd. and related companies with's FREE daily email newsletter.


Leave a Reply

Your email address will not be published. Required fields are marked *